Risk-Adjusted Hospital Rates Of Readmission And Mortality Using Comorbidity Data From A Clinical Registry Versus Administrative Claims

Abstract

Based on that discussion, the best practices are being revised in the form of an effectiveness guidance document and will be circulated for a targeted external review before being finalized and released. Results: Specific recommendations include: set forth all analytical plans and decision criteria a priori; design for three potential statistical adjustment methods; involve patients and other stakeholders early in the study design process; seek and evaluate external and observational data to help assess methodological assumptions and/or estimate counterfactual survival times; and regard informed consent as a continuous process and explain all treatment switching options. ConClusions: Adoption of these recommendations regarding treatment switching will help assure clearer evidence from oncology drug trials for decision makers. They will be publicly released in 2016.